(Sharecast News) - Oxford BioDynamics said on Thursday that interim results from its ongoing FDA-registered PROWES trial demonstrated that its EpiSwitch CiRT test had a significant impact on treatment decisions for cancer patients receiving immune checkpoint inhibitors.
The AIM-traded firm said the peer-reviewed study, published in the journal Cancers, assessed 205...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE